David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the most recent—and significant—advancements in the field of lung cancer.
Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of the phase Ib JAVELIN Solid Tumor Trial.
Researchers at the UC Davis Comprehensive Cancer Center are personalizing treatment using tumor xenografts in mice to test and identify more precise treatments for bladder cancer patients.
NCI-designated cancer centers are tasked with moving the field forward. It's a responsibility that everyone at UC Davis Comprehensive Cancer Center takes seriously.
Clinical trial designs are transforming dramatically
in order to expedite the discovery and validation
of new predictive biomarkers for patients
with non–small cell lung cancer and other
types of solid tumors.
Thomas J. Semrad, MD, assistant professor, co-director, Phase I Program, UC Davis Health System, discusses the Serial Patient-Derived Xenografts to Understand Cancer Therapy Resistance (SPIDER) program at UC Davis Health System, aimed at understanding patient resistance to cancer therapies.
Moon S. Chen Jr., PhD, MPH, associate director, Population Research and Cancer Disparities, professor, UC Davis Comprehensive Cancer Center, discusses various disparities in cancer care in underserved populations.
Megan E. Daly, MD, assistant professor of radiation oncology, UC Davis Cancer Center, discusses upcoming clinical trials involving radiation therapy for the treatment of lung cancer.